Oculis Holding AG

OCS • Biotechnology

$12.17

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$716.88M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 5.96Rentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 11 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$12.17

Change0.00%

Shares Out58.91M

Market Cap$716.88M

52W Range10.52 - 34.48

Beta0.13

P/E-10.99

P/S0.00

P/B6.62

P/FCF-83.46

EV/Sales0.00

EV/EBITDA-53.40

Price$12.17

Change0.00%

Shares Out58.91M

Market Cap$716.88M

52W Range10.52 - 34.48

Beta0.13

P/E-10.99

P/S0.00

P/B6.62

P/FCF-83.46

EV/Sales0.00

EV/EBITDA-53.40

EV/FCF-76.51

Earnings Yield-2.27%

FCF Yield-1.20%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio5.96

Quick Ratio5.96

Target$36.75

Target Upside201.97%

Target Median$38.00

Target Range26.00 - 45.00

Volume526.06K

Avg Volume673.78K

EPS Surprise-0.14

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

68/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 5.96Rentabilidad débil

Analyst view

Analyst sentiment and price target

OCS

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-26

Bajo

$26.00

Promedio

$39.40

Mediana

$38.00

Alto

$50.00

Resumen de la compañía

IPO: 5/18/2021

Industria: Biotechnology

P/B i: 6.62

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 5.96

Ratio rápido: 5.96

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Oculis Holding AG

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Fuente - Link

Competidores

ANAB BBOT KOD MNMD NKTR NRIX PHAT SANA URGN XNCR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announces that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON).

GlobeNewsWire

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

GlobeNewsWire

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a private translational neuroscience R&D company, today announced that Oculis and Accure have entered into an asset purchase agreement whereby, upon closing, Oculis will acquire all of Accure's worldwide development and commercial rights to Privosegtor. This acquisition will result in the termination of Oculis' existing license agreement with Accure, including associated milestone payments and royalties for each successful indication. This strategic transaction would enable Oculis to better harness Privosegtor's potential value going forward, without the encumbrance of the legacy license agreement with Accure, while retaining greater economic upside for the asset's future success as the Company continues to drive Privosegtor's development and pursue potential expansion opportunities.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-11	-0.49	-0.63	-0.14
2026-03-03	-0.47785	-0.51	-0.03215
2025-11-10	-0.5	-0.4	0.1
2025-08-21	-0.53	-0.59	-0.06
2025-05-08	-0.51	-0.77	-0.26
2025-03-11	-0.48	-0.76	-0.28
2024-11-07	-0.52	-0.55	-0.03
2024-08-27	-0.43	-0.56	-0.13
2024-05-08	-0.41	-0.44	-0.03
2024-03-18	-0.42	-0.38	0.04
2023-11-15	-0.36	-0.38	-0.02
2023-08-29	-0.33	-0.38	-0.05